Francisco Arnalich Fernández
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Telomere | 2 | 2018 | 146 | 1.25 | Why? |
| Urological Agents | 1 | 2019 | 24 | 0.78 | Why? |
| Femoral Vein | 1 | 2019 | 43 | 0.76 | Why? |
| Francisella | 1 | 2018 | 4 | 0.76 | Why? |
| Sildenafil Citrate | 1 | 2019 | 66 | 0.74 | Why? |
| Saphenous Vein | 1 | 2019 | 67 | 0.74 | Why? |
| Granulomatous Disease, Chronic | 1 | 2018 | 60 | 0.71 | Why? |
| Tenofovir | 2 | 2018 | 449 | 0.67 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.65 | Why? |
| AIDS Dementia Complex | 1 | 2013 | 48 | 0.50 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.49 | Why? |
| HIV-1 | 2 | 2017 | 3365 | 0.41 | Why? |
| HIV Protease Inhibitors | 1 | 2013 | 434 | 0.39 | Why? |
| Telomerase | 2 | 2018 | 45 | 0.36 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 952 | 0.34 | Why? |
| Venous Thrombosis | 2 | 2021 | 2739 | 0.33 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.28 | Why? |
| Sulfonamides | 1 | 2013 | 1294 | 0.27 | Why? |
| Ritonavir | 2 | 2021 | 4212 | 0.25 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.23 | Why? |
| Aging | 1 | 2017 | 3581 | 0.22 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.20 | Why? |
| Dideoxynucleosides | 1 | 2018 | 92 | 0.18 | Why? |
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2018 | 92 | 0.17 | Why? |
| Inappropriate Prescribing | 1 | 2021 | 284 | 0.17 | Why? |
| Protein Isoforms | 1 | 2018 | 347 | 0.17 | Why? |
| Umbilical Arteries | 1 | 2017 | 62 | 0.17 | Why? |
| Heart Block | 1 | 2017 | 59 | 0.16 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.16 | Why? |
| Obstetric Labor, Premature | 1 | 2017 | 114 | 0.15 | Why? |
| Sjogren's Syndrome | 1 | 2017 | 284 | 0.13 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.11 | Why? |
| Viral Load | 3 | 2018 | 15850 | 0.11 | Why? |
| Darunavir | 1 | 2013 | 477 | 0.10 | Why? |
| Eye Diseases | 1 | 2020 | 1150 | 0.09 | Why? |
| Spain | 4 | 2021 | 15545 | 0.09 | Why? |
| Neuropsychological Tests | 1 | 2013 | 954 | 0.09 | Why? |
| Anti-Bacterial Agents | 2 | 2021 | 10083 | 0.08 | Why? |
| Drug Resistance, Viral | 1 | 2013 | 1083 | 0.08 | Why? |
| Drug Administration Schedule | 1 | 2013 | 2324 | 0.08 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2017 | 1380 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Male | 9 | 2021 | 367725 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Radiography, Thoracic | 1 | 2018 | 5486 | 0.05 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Contact Lenses | 1 | 2020 | 108 | 0.05 | Why? |
| Humans | 14 | 2021 | 930598 | 0.05 | Why? |
| Pituitary Gland | 1 | 2018 | 65 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.04 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.04 | Why? |
| Ophthalmologic Surgical Procedures | 1 | 2020 | 211 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.04 | Why? |
| Female | 7 | 2021 | 380317 | 0.04 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Transfection | 1 | 2018 | 864 | 0.04 | Why? |
| Endoplasmic Reticulum | 1 | 2018 | 430 | 0.04 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
| Blood Safety | 1 | 2020 | 459 | 0.04 | Why? |
| Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
| Ultrasonography, Doppler | 1 | 2017 | 406 | 0.03 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.03 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| Registries | 2 | 2021 | 12327 | 0.03 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Adult | 3 | 2018 | 244371 | 0.03 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Aged | 3 | 2021 | 215776 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Cough | 1 | 2021 | 4891 | 0.02 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.02 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Ophthalmology | 1 | 2020 | 1840 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2021 | 243684 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |